MLYS

Mineralys Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website mineralystx.com
Employees(FY) 12
ISIN US6031701013

Performance

-5.83%

-12.5%

+18.64%

-3.08%

+46.51%

YTD

+95.96%

Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of MLYS 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the bearish outlook. This combination points to a challenging environment for the stock, with potential for further declines.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MLYS

Stock Rank

Recent News & Updates

2024-11-12 23:00
Mineralys Therapeutics Announces Q3 2024 Results and Updates(TipRanks)
2024-11-12 10:12
Q3 2024 Mineralys Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
2024-11-11 16:56
Mineralys Therapeutics Q3 Net Loss Widens(MT Newswires)
2024-11-11 16:05
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-11-11 03:05
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-05 16:05
Mineralys Therapeutics to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-11-05 03:05
Mineralys Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-04 16:05
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024(GlobeNewswire)
2024-11-04 03:05
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024(Globenewswire)
2024-10-30 08:00
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension(GlobeNewswire)
2024-10-29 20:00
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension(Globenewswire)
2024-10-22 08:00
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024(GlobeNewswire)
2024-10-21 20:00
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024(Globenewswire)
2024-10-20 09:10
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate(Simply Wall St.)
2024-09-25 08:00
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension(GlobeNewswire)
2024-09-24 20:00
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension(Globenewswire)
2024-08-28 08:00
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference(GlobeNewswire)
2024-08-27 20:00
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference(Globenewswire)
2024-08-13 16:05
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(GlobeNewswire)
2024-08-13 04:05
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-08-05 16:05
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024(GlobeNewswire)
2024-08-05 04:05
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024(Globenewswire)
2024-07-12 19:01
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares(GuruFocus.com)
2024-07-12 19:01
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares(GuruFocus.com)
2024-07-10 08:04
HC Wainwright Initiates Mineralys Therapeutics at Buy Rating With $30 Price Target(MT Newswires)
2024-06-21 03:11
Insider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)(GuruFocus.com)
2024-06-20 17:49
Mineralys Therapeutics Insider Sold Shares Worth $592,022, According to a Recent SEC Filing(MT Newswires)
2024-06-15 02:53
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares(GuruFocus.com)
2024-06-14 08:00
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors(GlobeNewswire)
2024-06-14 02:43
Insider Sale: CFO and Secretary Adam Levy Sells 96,815 Shares of Mineralys Therapeutics Inc (MLYS)(GuruFocus.com)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.